Add Yahoo as a preferred source to see more of our stories on Google. HOLLYWOOD, CALIFORNIA - MARCH 12: Colin Farrell attends the 95th Annual Academy Awards on March 12, 2023 in Hollywood, California.

Add Yahoo as a preferred source to see more of our stories on Google. The rare neurogenetic disorder affects 1 in 15,000 people For the first time, Colin Farrell has opened up his home and talked ...

OV101 program in Angelman syndrome to pause pending full analysis of NEPTUNE trial and discussions with FDA Pivotal studies of OV935 (soticlestat) in Dravet syndrome and Lennox-Gastaut syndrome ...

Ultragenyx (RARE) Pharmaceutical announced that the first patient has been dosed in the pivotal Phase 3 Aspire study, NCT06617429, evaluating the efficacy and safety of GTX-102, its investigational ...

NOVATO, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (RARE) today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to ...

Ultragenyx has found early success with its experimental treatment for the rare disease Angelman syndrome, supporting the company’s decision to acquire its development partner two years ago.

Expansion Cohorts showed rapid, clinically meaningful improvement across multiple domains; improvements consistent or exceeding Dose-escalation Cohorts data at Day 170 Additional long-term data in ...

ORLANDO, Fla.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, announced today that ...

Company expects to complete Phase 3 Aspire study in the second half of 2026 Aurora study of GTX-102 in additional ages and genotypes on track to initiate in the second half of 2025 “The accelerated ...

Neurons with a fluorescent reporter for paternal UBE3A gene activity show only a background low fluorescent glow when treated with a vehicle control, but show a bright fluorescent glow when treated ...

Angelman syndrome is a rare genetic disorder caused by mutations in the maternally-inherited UBE3A gene and characterized by poor muscle control, limited speech, epilepsy, and intellectual ...